Lynn
0000-0002-0523-4346
1 paper found
Refreshing results…
A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy
Missing publications? Search for publications with a matching author name.